Immune checkpoint inhibitors are cancer medicines, a type of immunotherapy, used for many cancers like melanoma and lung cancer. They are usually given as an infusion into a vein, and some can be given as a shot under the skin. They work by taking the brakes off your immune system so it can find and attack cancer cells.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Immune checkpoint inhibitors are a type of cancer immunotherapy. Rather than attacking cancer cells directly, as chemotherapy does, they help the person's own immune system recognize and fight the cancer. Familiar examples include pembrolizumab (Keytruda), nivolumab (Opdivo), cemiplimab (Libtayo), atezolizumab (Tecentriq), durvalumab (Imfinzi) and ipilimumab (Yervoy). Opdualag combines nivolumab with a newer checkpoint drug, relatlimab, for advanced melanoma. These medicines are approved for many cancers, including melanoma and other skin cancers, lung, kidney, bladder, head and neck, liver, stomach, cervical and colorectal cancers, and Hodgkin lymphoma. Some are used for advanced cancer that has spread; others are given before or after surgery to lower the chance of the cancer coming back. They may be used alone or with chemotherapy or other cancer drugs. Each drug has its own list of approved cancers and situations. For some uses, the tumor must first test positive for a specific marker, such as PD-L1 (a protein that some tumors produce in large amounts) or a defect in the tumor's ability to repair DNA copying errors (described as MSI-high or mismatch repair deficient).
The immune system has built-in brakes, called checkpoints, that keep it from attacking healthy tissue. T cells, the white blood cells that kill infected or abnormal cells, carry checkpoint proteins such as PD-1 and CTLA-4 on their surface. When a checkpoint protein connects with its partner protein on another cell, it sends the T cell an "off" signal. Some cancers exploit this system. A tumor that makes large amounts of PD-L1, the partner of PD-1, can switch off the T cells that would otherwise attack it. Checkpoint inhibitors are lab-made antibodies that block this connection. PD-1 blockers (such as Keytruda, Opdivo and Libtayo) and PD-L1 blockers (such as Tecentriq and Imfinzi) work on the same brake from opposite sides. Ipilimumab blocks a different brake, CTLA-4, and is often combined with a PD-1 blocker. Releasing these brakes explains both the benefit and the main risk. The freed-up T cells can attack the cancer, but they can also attack healthy organs, causing inflammation that resembles an autoimmune disease.
Most checkpoint inhibitors are given in a clinic or infusion center as an infusion into a vein (IV). Pembrolizumab, for example, is infused over about 30 minutes every 3 or 6 weeks. Some medicines now have versions injected under the skin of the thigh or abdomen over a few minutes, such as Keytruda Qlex, Opdivo Qvantig and Tecentriq Hybreza. These are given by a healthcare provider and use different doses from the IV forms, so one cannot simply be swapped for the other. How long treatment lasts depends on the drug and the reason for using it. For advanced cancer, PD-1 and PD-L1 blockers are often continued as long as they are working and tolerated, commonly up to about two years. When given after surgery to prevent the cancer from returning, treatment is often limited to about a year. Ipilimumab is usually given as a short course of up to four doses. Doses may be delayed or stopped because of side effects, and this is a normal part of treatment rather than a mistake.
Tiredness, rash, itching, diarrhea, decreased appetite, joint or muscle aches and an underactive thyroid are among the more common side effects. When a checkpoint inhibitor is combined with chemotherapy, side effects of the chemotherapy, such as nausea, hair loss and nerve tingling, are added on. The side effects that need the most attention are immune-related: the immune system inflames a healthy organ. This can happen in almost any part of the body, including the lungs, intestines, liver, hormone glands, kidneys, skin, nerves, eyes and heart. Many are manageable, but some are severe and, rarely, fatal. They can start weeks or months into treatment, or even after treatment has ended. Combinations, especially those including ipilimumab, cause these problems more often than a single PD-1 or PD-L1 drug. Contact the cancer care team right away about any new or worsening symptom, even one that seems minor. Important examples include a new cough or shortness of breath; diarrhea, more frequent bowel movements or blood in the stool; yellowing skin or eyes or dark urine; headaches that won't go away, unusual tiredness, dizziness, or unusual thirst and urination; a rash with blistering, peeling or mouth sores; and muscle weakness, numbness, confusion, vision changes, chest pain or an irregular heartbeat. Prompt treatment can keep these reactions from becoming more serious. Treatment usually means corticosteroids (anti-inflammatory steroid medicines) or hormone replacement, and pausing or stopping the checkpoint inhibitor. Some effects on hormone glands are permanent. For example, an underactive thyroid caused by treatment usually needs lifelong thyroid hormone, and rarely the treatment triggers type 1 diabetes, which needs insulin. Reactions during the infusion itself, such as chills, flushing or wheezing, are uncommon and are handled by the infusion staff.
Checkpoint inhibitors are not known for the drug-to-drug interactions common with many pills, but certain health conditions change the balance of risk. Before starting, tell the team about any autoimmune disease (such as Crohn's disease, ulcerative colitis, or lupus), an organ or corneal transplant, a nervous system condition such as myasthenia gravis, or past radiation to the chest. These do not always rule out treatment, but an autoimmune disease can flare and a transplanted organ can be rejected. People who have had, or may later need, a stem cell transplant from a donor face a risk of serious transplant complications, including graft-versus-host disease, in which donor immune cells attack the body. This needs to be part of the planning discussion. These medicines can harm a developing baby. People who could become pregnant need a pregnancy test before starting and effective birth control during treatment and for several months after the last dose (four months for pembrolizumab), and breastfeeding is not recommended over the same period. Because immune reactions can appear later, any doctor or emergency team treating someone during or after checkpoint inhibitor treatment should be told about it.
Before each treatment, the team usually checks how the person is feeling and runs blood tests, including liver, kidney and thyroid tests, to spot immune side effects early. Scans are repeated at intervals to see how the cancer is responding. Response varies widely. Only some people respond: in some, tumors shrink or stop growing, while other cancers keep growing despite treatment. The chance of benefit depends on the type of cancer, its stage and tumor features such as PD-L1 levels, which is why some uses require a positive tumor test first. If an immune side effect develops, steroid treatment often lasts a month or more and is tapered gradually rather than stopped suddenly. Depending on the severity of the reaction, the checkpoint inhibitor may be restarted afterward or stopped for good. Watching for new symptoms continues after the last dose.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Immune Checkpoint Inhibitors, what you've noticed, or ask the community a question.